Sanofi, Glaxo Join Forces to Develop Coronavirus Vaccine

  • Partnership brings together two of the biggest vaccine makers
  • Manufacturing is among the key hurdles in race for shot

A Sanofi logo sits on the company's headquarters in Paris.

Photographer: Marlene Awaad/Bloomberg
Lock
This article is for subscribers only.

Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.

Two of the world’s biggest vaccine makers are joining forces to tackle the coronavirus as the number of confirmed infections approaches 2 million worldwide.